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Abstract
There is evidence that immune-activated macrophages infected with the Human Immunodeficiency Virus (HIV) are
associated with tissue damage and serve as a long-lived viral reservoir during therapy. In this study, we analyzed 780 HIV
genetic sequences generated from 53 tissues displaying normal and abnormal histopathology. We found up to 50% of the
sequences from abnormal lymphoid and macrophage rich non-lymphoid tissues were intra-host viral recombinants. The
presence of extensive recombination, especially in non-lymphoid tissues, implies that HIV-1 infected macrophages may
significantly contribute to the generation of elusive viral genotypes in vivo. Because recombination has been implicated in
immune evasion, the acquisition of drug-resistance mutations, and alterations of viral co-receptor usage, any attempt
towards the successful eradication of HIV-1 requires therapeutic approaches targeting tissue macrophages.
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Introduction
The intra-host evolution of HIV-1 is characterized by the ability
of the virus to generate, on a daily basis, an extensive sequence
diversity due to the high mutation rate of reverse transcriptase
(3610
25 substitutions per site per generation) [1], rapid viral
turnover (10
28 to 10
29 virions per day) [2–4], large number of
infected cells (10
7 to 10
8 cells) [5], and recombination [6,7].
Recombination plays a significant role in generating genetic
variation in the HIV-1 genome [8] and it has been shown that the
mean recombination rate can be up to 5.5 times greater than the
mean mutation rate [9]. Recombination can occur when cells are
super-infected with different viral strains [10], leading to
exchanged genetic segments in the progeny virus and the rapid
generation of completely novel and elusive genotypes within the
infected individual [9,11–13]. Laser micro-dissection studies have
shown that individual cells are able to harbor up to ten unique
viruses [12]. Recombination is, therefore, one of the most
dramatic means for a virus like HIV to generate diversity and it
has been implicated in immune evasion and escape [11,14], the
potential to generate drug-resistance mutations [15,16], and the
switch of co-receptor usage from CCR5 to CXCR4 [17,18].
However, the extent of viral recombination in different lymphoid
and non-lymphoid tissues infected in vivo by HIV-1, as well as the
relationship between recombination and pathogenesis in AIDS
patients, are currently unknown.
The causes of death for HIV-infected individuals are numerous
and have changed since the introduction of highly-active
antiretroviral therapy (HAART), although several AIDS-defining
illnesses, including non-Hodgkin’s lymphoma, dementia, Pneumo-
cystis carinii infection, atypical mycobacteria infection, and brain
toxoplasmosis, still persist. In the United States, the incidences of
non-AIDS defining diseases, such as HCV infection, non-AIDS-
defining lymphomas, cardiovascular disease, liver dysfunction, and
splenomegaly have also increased along with the life span of HIV-
infected individuals [19]. Although T-cell depletion is character-
istic of AIDS, macrophage infection is also an important
component during the progression of HIV infection to AIDS. In
the case of AIDS dementia, macrophages and microglia are the
primary immune cells causing destruction of neuronal tissues. In
the case of AIDS related lymphomas, it has been hypothesized that
macrophages may be B-cell mitogens, thus contributing to the
development of the disease [20]. In sheep, the Maedi-Visna virus
infection, which targets macrophages and dendritic cells but not
T-lymphocytes, also leads to progressive diseases and death that
resembles the wasting and brain diseases of HIV without the T-cell
immunodeficiency [21]. In HIV-infected humans, tissue-based
abnormalities discovered at autopsy could be linked to long-term
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antiretroviral drugs; therefore, the characterization of HIV-1
variants infecting tissues with abnormal histopathology may shed
light on the important relationship between viral diversity and
pathogenesis.
In the present study, we examined 780 HIV-1 envelope gp120
sequences amplified from lymphoid and non-lymphoid tissues
displaying different degrees of histopathology from seven patients
who died with a variety of end-stage HIV-associated diseases. Four
of the patients were on HAART therapy near or at the time of
death. The comparison of brain and lymphoma tissues to
lymphoid tissues allowed the evaluation of macrophage-localized
HIV (brain) as compared tissues that may contain a mixed
population of macrophage and T-cell associated HIV tissues
(lymphoid tissue). By using a number of robust statistical tests to
detect intra-host recombination, we identified the presence of
recombinant sequences in different tissues and correlated the
extent of recombination with precise details relating to autopsy
and tissue pathology reports.
Results
Case studies and tissue histopathology
HIV-1 envelope gp120 sequences were amplified successfully
from 53 normal and abnormal tissues collected post mortem from
seven patients who died of AIDS. Two patients (CX and GA) had
progressive HIV-associated dementia (HAD), three died of non-
Hodgkin’s lymphoma (AM, IV, BW), and two of systemic
infections (AZ, DY). Extensive details about each case study are
included in the Supporting Material S1. The autopsies were
performed at various locations in the United States from 1995 to
2003. Although every attempt was made to amplify sequences
from identical tissues from all patients, this was impossible due to
several factors, including the fact that many brain tissues,
especially from those patients without extensive brain disease,
contained no amplifiable HIV.
Tissues were grouped and analyzed according to 1) histopathol-
ogy: 11 normal tissues vs. 39 abnormal tissues (three tissues did not
have an associated histology report) or 2) in terms of the primary
disease of the infected subjects, such as dementia (14 tissues from
subjects CX and GA), lymphoma (26 tissues from subjects IV, AM
and BW), and other complications (8 tissues from subject DY who
died from Mycobacterium avium complex infection and 5 tissues from
subject AZ who had severe cardiovascular disease, including
atherosclerosis in brain tissues and chronic hepatitis C infection).
Figure 1 shows three examples of macrophage-specific CD68
staining in meninges, lymph node and spleen from subjects with
dementia, lymphoma and systemic infection respectively. In
general, most tissues were highly positive for CD68 staining
(tissue macrophages), and moderately positive for p24 staining.
When present, the p24 stained cells were only tissue macro-
phages (data not shown). CD68 staining would be negative in
normal brain tissues. Finding these cells in the brain at the same
frequency as in the spleen and lymph nodes highlights the
importance of the frequency and potential importance of CD68
macrophages in the pathogenesis of brain disease. The p24 co-
localization observed in the brain was only found in the CD68
cell population. This, therefore, provided strong evidence that at
least a subpopulation of the abnormally present macrophages
expressed virus and would be in an activation state. No Mac387
staining was present in pathologic brain and lymphoma tissues
suggesting that the CD68 expressing cells present in those tissues
were relatively long lived.
Variable frequency of HIV-1 intra-host recombination in
different tissues
Recombinants were identified using two methods. The first
method, described in detail in Salemi et. al. [22], was specifically
designed to identify recombinants within highly related sequences.
In brief, for each patient, a split-decomposition graph including
sequences amplified from each tissue was obtained with the
Neighbor Net algorithm [23]. Some graphs showed intricate
networks consistent with the existence of conflicting phylogenetic
signals and extensive intra-host recombination. We tested the
hypothesis of intra-tissue recombination in each graph by using the
pair-wise homoplasy index (PHI-test), which simulations have
shown to provide a robust and reliable statistic to detect
recombination [24]. The PHI statistic quantifies the incompati-
bility between different possible phylogenetic histories underlying
the data. For each alignment of viral sequences from a tissue, we
calculated the observed PHI and a null PHI distribution obtained
from 1000 random alignments simulated under the null hypothesis
of no recombination. An observed PHI value,5% of the values in
the null distribution is evidence of a statistically significant signal
for recombination. In many tissues the PHI test for recombination
was highly significant (p,0.0001). Interestingly, while HIV-1
recombinants were detected in all patients, regardless of pathology
and cause of death, they occurred in highly different proportions,
ranging from 0% to 53% in different tissues (Tables 1–7). The
removal of recombinant sequences significantly changed the
Figure 1. Histopathology. Anti-CD68 staining of A) meninges from patient CX; B) large cell lymphoma from AM; and C) spleen from patient DY.
CD68 positive cells are stained brown.
doi:10.1371/journal.pone.0005065.g001
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containing recombinants. Although recombinants were often
found in tissue sequence populations with high divergence, they
were also found in sequence populations with a comparatively low
sequence divergence (this is especially apparent in the two
lymphoma cases). Linear regression analysis comparing the
number of recombinants to the diversity in each tissue showed a
significant correlation of the two variables only in subject AZ
(r=0.96, p=0.01). Therefore, we could exclude, as previously
shown [22,24], that the PHI test is biased by the extent of
heterogeneity within a given data set or that higher diversity and
recombination values are due to rapid viral replication in disease
Table 1. Patient CX - Dementia.
Tissue # Sequences PHI-test p-value
# Recombinants
Identified (%
recombinant) % Diversity (SE)
% Diversity without
Recombinants (SE)
A-Perivascular LN 23 0.256 0 1.4 (0.1) nc
N-Colon 24 0.900 0 2.0 (0.3) nc
U-Periventricular White 24 0.393 0 0.8 (0.1) nc
A-Choroid Plexus 23 0.076 0 1.6 (0.1) nc
A-Meninges 23 0.0(,10
299) 5 (21.7) 3.9 (0.3) 3.1 (0.4)
A-Temporal Lobe 22 0.170 0 1.0 (0.1) nc
A-Basal Ganglia 23 1.198(10
213) 5 (21.7) 4.0 (0.4) 3.7 (0.3)
A-Occipital Junction 23 5.871(10
211) 8 (34.8) 4.3 (0.4) 4.2 (0.4)
A-Occipital White Matter 24 2.014 (10
213) 9 (37.5) 2.1 (0.2) 1.8 (0.2)
Recombination in and between tissues. The subjects in the study are listed in Tables 1–7. Each table lists the tissues sampled, the number of sequences obtained
from each tissue, the p-value for the PHI-test computed with Splitstree and the number and percent of recombinants found in the data set. The percent diversity in each
tissue sequence dataset is shown with a standard error. For comparison, the percent diversity was also calculated without recombinants sequences included. Numbers
highlighted in grey indicate significant p-values for recombination in the data set or a greater than 1% change in the % diversity of the sample set when the
recombinant sequences were removed. Letter designations before the tissue names refer to pathology reports, A=abnormal, N=normal and U=unknown (no support
for tissue pathology is written in the autopsy report). nc=No change in diversity calculation.
Recombination tests. The number of recombinant sequences for all tissues in each patient is shown for the PHI-test and the RDP recombinant detection methods in
Table 8.
doi:10.1371/journal.pone.0005065.t001
Table 2. Patient GA - Dementia.
Tissue # Sequences PHI-test p-value
# Recombinants
Identified (% recombinant) % Diversity (SE)
% Diversity without
Recombinants (SE)
A-Meninges 23 7.438(10
215) 7 (30.4) 2.7 (0.3) 2.7 (0.3)
A-Frontal Lobe White 31 3.492(10
214) 13 (41.9) 6.2 (0.5) 2.2 (0.2)
A-Temporal Cortex 21 0.002 2 (9.5) 5.8 (0.5) 1.5 (0.2)
N-Lymph Node 28 0.0(,10
299) 9 (32.1) 4.7 (0.4) 4.7 (0.3)
A-Spleen 29 0.0(,10
299) 4 (13.8) 3.4 (0.3) 3.4 (0.3)
doi:10.1371/journal.pone.0005065.t002
Table 3. Patient DY – Systemic Infection (including encephalitis).
Tissue # Sequences PHI-test p-value
# Recombinants
Identified (% recombinant) % Diversity (SE)
% Diversity without
Recombinants (SE)
N-Meninges 18 0.0(,10
299) 4 (22.2) 2.8 (0.3) 2.2 (0.3)
N-Basal Ganglia 20 0.003 1 (5.0) 2.3 (0.3) 0.7 (0.1)
N-Temporal Cortex 23 1.0 0 0.3 (0.1) nc
N-Frontal Lobe Grey 22 2.101(10
24) 1 (4.5) 2.7 (0.3) 2.7 (0.3)
N-Frontal Lobe White 24 0.188 0 0.8 (0.1) nc
U-Liver 17 0.120 0 0.9 (0.2) nc
A-Lymph Node 21 1.737(10
27) 5 (23.8) 3.3 (0.3) 3.0 (0.3)
A-Spleen 21 2.320(10
24) 2 (9.5) 3.0 (0.3) 2.6 (0.3)
doi:10.1371/journal.pone.0005065.t003
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was usually found in abnormal tissues associated with disease
processes, including meninges, spleen and lymph nodes. No
relationship between a patient’s HAART history and the
number of recombinants found in damaged or normal tissues
was observed.
The RDP program was also used to detect the number of
recombinants in each tissue and produced similar results [25].
RDP is a useful software package for the rapid and automatic
identification of recombination signals. The default setting uses
seven different recombination detection methods. These are, 1) the
original RDP method, 2) the Bootscan/RECSCAN method
[25,26], 3) the method applied in the program GENECONV
[27,28], 4) the MaxChi method [29,30], 5) the Chimaera method
[29], 6) the SiScan method [31] and 7) the 3SEQ method [32].
The numbers of recombinants for each subject’s tissues were
combined and are shown in Table 8 along with the results from
the Salemi et al method. In all but one subject (AM), the RDP
Table 4. Patient AZ – CVD and Systemic Infection.
Tissue # Sequences PHI-test p-value
# Recombinants Identified
(% recombinant) % Diversity (SE)
% Diversity without
Recombinants (SE)
N-Meninges 13 0.126 0 0.9 (0.2) nc
N-Frontal Cortex 22 1.0 0 0.4 (0.1) nc
A-Liver 17 1.0 0 0.6 (0.1) nc
N-Lymph Node 16 2.172(10
24) 1 (6.3) 4.0 (0.3) 3.6 (0.3)
A-Spleen 19 9.135(10
29) 2 (10.5) 4.7 (0.4) 4.8 (0.4)
doi:10.1371/journal.pone.0005065.t004
Table 5. Patient AM - Lymphoma.
Tissues # Sequences PHI-test p-value
# Recombinants
Identified (%
recombinant) % Diversity (SE)
% Diversity without
Recombinants (SE)
A-Left Axillary LN 22 0.336 0 0.9 (0.1) nc
N-Diaphragm 20 0.992 0 5.8 (0.4) nc
U-Prostate 16 1.0 0 2.3 (0.3) nc
A-Kidney 21 1.0 0 1.2 (0.2) nc
A-Liver 1 Biopsy 20 0.022 1 (5.0) 1.6 (0.2) 1.5 (0.2)
A-Liver 2 Biopsy 37 6.378(10
28) 3 (8.1) 1.1 (0.2) 1.0 (0.2)
A-Liver 3 Biopsy 20 0.001 2 (10.0) 1.9 (0.2) 1.5 (0.2)
A-Right Axillary LN 18 3.344(10
24) 2 (11.0) 1.6 (0.2) 1.5 (0.2)
A-Spleen 24 5.072(10
28) 7 (29.2) 2.4 (0.3) 2.2 (0.3)
A-Stomach Lymphoma 27 7.409(10
210) 4 (14.8) 1.3 (0.1) 0.3 (0.1)
doi:10.1371/journal.pone.0005065.t005
Table 6. Patient IV - Lymphoma.
Tissues # Sequences PHI-test p-value
# Recombinants Identified
(% recombinant) % Diversity (SE)
% Diversity without
Recombinants (SE)
A-Diaphragm 16 0.003 1 (6.3) 1.7 (0.2) 1.7 (0.2)
A-GI Tract 18 1.0 0 2.9 (0.3) nc
A-Kidney 19 0.353 0 0.6 (0.1) nc
A-Left Axillary LN 13 2.912(10
25) 4 (30.8) 2.4 (0.3) 2.4 (0.3)
A-Lung LN 22 1.637(10
213) 11 (50.0) 2.7 (0.3) 2.7 (0.3)
A-Periaortic LN 20 4.722(10
29) 3 (15.0) 2.5 (0.3) 2.5 (0.3)
A-Right Axillary LN 16 2.432(10
26) 4 (25.0) 2.4 (0.3) 2.3 (0.3)
A-Spleen 19 3.624(10
25) 2 (10.5) 1.9 (0.2) 1.9 (0.2)
A-Stomach 22 1.0 0 0.3 (0.1) nc
A-Omental LN 16 0.762 0 1.8 (0.2) nc
doi:10.1371/journal.pone.0005065.t006
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the Salemi et al. method, at least in the case of intra-patient tissue
recombination detection, is more conservative. This is probably
because 1) some of the methods in RDP are molecular model-
dependant, 2) the number of sequences within each analysis can
impact results, and 3) variation within each population may alter
the number of recombinants identified [33]. The significant
finding from both analyses is that recombination occurred
frequently, in various places along the gp120, and at various
frequencies in the many tissues examined.
Tissue histopathology and recombination
Both normal and abnormal tissues were sampled from five (CX,
GA, DY, AZ, AM) out of seven patients. For two patients, IV and
BW, all tissues sampled were identified as abnormal. Figure 2A
shows for each subject the percentage of normal and abnormal
tissues harboring recombinants. In general, the proportion of
tissues harboring recombinant sequences was significantly higher
among tissues with abnormal histopathology than in normal
tissues (chi-square test for categorical data p,0.001), with the
exception of one subject (GA). Statistical analysis also showed that
a significantly higher proportion of recombinant sequences was
detected within these abnormal tissues (chi-square test for
categorical data p,0.001) as compared to normal tissues, with
the exception, again, of subject GA (Figure 2B). Although a higher
frequency of recombinant sequences was more likely to be found
in tissues displaying abnormal histopathology, no significant
difference was found in the extent of recombination by comparing
patients with different AIDS-associated illnesses. The box-plot in
Figure 3 shows that the range of recombinant sequences detected
within patients grouped according to their diagnosis was largely
overlapping.
Patient GA contained a relatively equal number of recombi-
nants in one normal tissue: an axillary lymph node. This tissue also
had the second highest diversity rate of all 53 tissues examined;
therefore, this may be a single case where the number of
recombinants was due to high viral turnover in this particular
tissue at the time of death or due to other unknown factors.
Further evaluation of other normal tissues from patient GA may
provide evidence to establish whether the association between
recombination in this case was tissue-specific or due to an overall
different pattern of sequence evolution within the patient.
Identification of recombination breakpoints
While the detection of recombinant sequences is readily
achievable, the detection of the precise location of a breakpoint
is nearly impossible, especially in the case of highly related
sequences. Still, recombination breakpoints were assessed in order
to identify if potential hotspots or non-specific recombination
events had occurred. The analysis was conducted using the split-
decomposition networks in conjunction with visual examination of
bootscans produced with Simplot [34]. As suggested by Zhang et
al. [35], we used a small moving step (20 nt) for breakpoint
detection; however, by varying the sliding window from 1 to 20 nt,
we found that putative breakpoints could map within a genomic
region of approximately 20 to 100 nucleic acids; therefore, it is
important to emphasize that the breakpoints are not precise but
merely provide a graphical overview of our findings. An example
of our method (patient CX meninges) is given in Figure 4.
Figure 4A shows the Neighbor-Net inferred tree using viral
sequences from the meninges of subject CX. Putative recombinant
sequences, usually located at the vertices of large splits in such
networks, are highlighted within a solid circle, while broken circles
indicate monophyletic groups of putative parental sequences. The
bootscanning analysis shown in Figure 4B shows how putative
breakpoints appear in the plot as a switch in a high bootscan value
from one sequence to another related sequence. This analysis was
performed for all 127 identified recombinant sequences (data
available as supplemental material).
Figure 5 displays a map of the putative breakpoints for all
recombinant sequences in each patient. The breakpoints are color-
coded by tissue. Many of the sequences contained multiple
breakpoints so that the number of breakpoints on each graph is
typically larger than the number of recombinant sequences listed
in Tables 1–7. In most patients putative breakpoints along the
gp120 appeared somewhat randomly distributed in both con-
served and variable gp120 domains. However, in some cases
similar breakpoints clustered to specific regions along the genome,
suggesting the possibility of recombination hotspots or selective
outgrowth of particular viral variants. As an example, subject GA
Table 7. Patient BW – Lymphoma (including leptomeningeal lymphoma).
Tissue # Sequences PHI-test p-value
# Recombinants
Identified (%
recombinant) % Diversity (SE)
% Diversity without
Recombinants (SE)
A-Meninges 22 2.508(10
29) 5(22.7) 2.5 (0.3) 2.1 (0.2)
A-Basal Ganglia 23 0.175 0 0.9 (0.1) nc
A-Temporal Cortex 17 1.000 0 0.3 (0.1) nc
A-Frontal Lobe Gray 21 0.091 0 0.3 (0.1) nc
A-Frontal Lobe White 20 0.276 0 0.9 (0.2) nc
A-Spleen 18 0.074 0 1.7 (0.2) nc
doi:10.1371/journal.pone.0005065.t007
Table 8. Recombination tests.
Patient PHI-test method RDP method
CX 27 35
GA 35 40
DY 13 21
AZ 3 4
AM 19 10
IV 25 33
BW 5 16
doi:10.1371/journal.pone.0005065.t008
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the V3 domain. Subjects CX, GA and IV all have clusters of
recombinant breakpoints occurring around the end of V2 domain.
Alternatively, the apparent random distribution of breakpoints
could be due solely to the inability to identify the precise location
of breakpoints; however, with the analysis of 127 total recombi-
nant sequences, it is unlikely that bootscanning would be so
imprecise as to provide such diverse results over a region of 1200
nucleic acids.
Both dementia patients contained numerous intra-tissue recom-
binants with many sequences containing multiple breakpoints
along gp120. These patients had putative breakpoints mapping
within the first four hypervariable domains. In contrast, patients in
the ‘‘systemic’’ disease classification contained fewer recombinant
breakpoints overall. Although no brain sequences were available
for the lymphoma patients AM and IV, their breakpoint results
looked somewhat similar to the dementia patients. This may be
due to the fact that both dementia and lymphoma are
macrophage-mediated diseases. Interestingly, none of the subjects
showed any recombination occurring in either the far 59 or 39 end
of the genome, including the V5 domain.
Figure 2. Frequency of recombination. In panel A the graph shows for each subject (x-axis), the percentage of tissues harboring recombinants
(y-axis). In panel B the graph shows the percent of recombinant sequences found in normal and abnormal tissues for each subject. Tissues with
normal and abnormal histopathology are indicated in yellow and purple respectively. * Only tissues with abnormal histopathology were collected
from patient IV and BW.
doi:10.1371/journal.pone.0005065.g002
Figure 3. Distribution of HIV-1 recombinant sequences in
subjects with different primary diseases. Each box plot shows the
median, the 95-percentile distribution of the proportion of recombi-
nants detected in tissues (y-axis) sampled from patients with different
primary diseases (x-axis) and associated standard errors.
doi:10.1371/journal.pone.0005065.g003
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Recombination plays a major role in HIV-1 evolution and
representsa powerfulmechanismtoproducegeneticdiversityduring
the viral lifecycle. Although recombination in HIV-1 viruses has
been well documented, especially between different subtypes within
an individual or in the context of circulating recombinant forms in a
population of infected subjects, it has been less studied in the context
of its occurrence within individuals. The present study represents the
most extensive investigation of HIV-1 intra-host recombination
within different tissues performed to date. Seven hundred eighty
gp120 sequences amplified from 53 tissues with either normal or
abnormal histopathology were collected from seven patients who
died of different AIDS-associated illnesses.
One characteristic of end-stage AIDS is the presence of HIV
p24 expressing macrophages along with T-cell depletion. At end-
stage disease, Mack et. al. [36], found that in a large variety of
autopsy tissues classified as diseased tissues, including lymph
nodes, spleen and brain, with amplifiable amounts of DNA, p24
antigen staining was predominantly localized to macrophages
interspersed in a background of p24-negative lymphocytes. This
type of staining was not seen in non-diseased tissues in HIV
positive patients [36]. We found a similar staining pattern in the
tissues used for this study. The higher frequency of recombinant
sequences consistently found in tissues with abnormal histopathol-
ogy is likely explained by the fact that such tissues display
increased macrophage proliferation due to an inflammatory
response. HAART therapy, which was given to four of the seven
patients prior to death, appeared to have little effect on overall
recombination rates. This is not unexpected, since macrophages
are one of the most important cellular reservoirs sustaining virus
replication during HAART [37]. In fact, several studies have
implicated HAART therapy in the development of metabolic lipid
dysfunction and other disorders that can lead to tissue abnormal-
ities [38–40]. The results strongly implicate macrophages as the
primary producers of recombinants in damaged tissues. Tissue
samples taken over time from an animal model would confirm if a
similar association between recombination and abnormal tissues
are typical in early and mid-stage, rather than only at end-stage
disease.
HIV integration within host cell genomic DNA is a required
step of the viral infection cycle. HIV integration site mapping and
laser capture micro dissection analysis of infected macrophages
have shown that viral integration usually occurs within introns of
genes related to or near cellular activation loci [36]. It is interesting
to note that the brain specimens used to map insertion sites in
Mack et al. [36] were also analyzed in the current study (patient
CX), demonstrating that high recombination rates occur within
brain macrophages that contain inserted forms of HIV. Sequences
from patient CX were also analyzed using a phylodynamic
approach [41]. This study showed that activated macrophages
migrate between HIV infected brain tissues and especially to areas
of the brain where there is an abundance of tissue damage.
Persistent macrophage activation is associated with an inhibition of
Figure 4. Recombination analysis of HIV-1 gp120 sequences from the meninges of subject CX. A. Neighbor-Net (NNet) obtained with the
split-decomposition method and uncorrected p-distances for HIV-1 gp120 sequences amplified from meninges. Solid and broken circles highlight
putative recombinant and parental sequences, respectively. A colored box indicates a monophyletic group of putative parental sequences to be
tested in the bootscanning analysis B. Bootscanning plots of three recombinant sequences. Each bootscanning was carried out on an alignment that
included a query sequence (the putative recombinant), and a set of putative parental sequences (indicated by different colors corresponding to the
colored boxes in panel A. The query sequence (within the solid circles in panel A) is given at the top of each bootscanning plot. The x-axis represents
the nucleotide position along the alignment; the y-axis represents the % bootstrap support for the clustering of the query sequences with one of the
monophyletic groups in panel A. The crossing point between two lines of different color, indicated by a vertical solid line, specifies the assumed
position of a recombination breakpoint.
doi:10.1371/journal.pone.0005065.g004
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survival advantage, the ability to act as a continuous source of HIV
and to serve as a long-term reservoirs/sites of viral recombination
[42]. Furthermore, tissue macrophages co-infected with opportu-
nistic pathogens such as Mycobacterium Avian Complex (MAC) or
Pneumocystis carinii dramatically increase viral production and the
likelihood of macrophage-mediated tissue destruction [43].
The occurrence of HIV-1 recombination in vivo can be
explained by the ability of the nascent viral strand to switch
RNA templates during reverse transcription [44], and it
necessitates super-infection of the target cell with two or more
viruses, each carrying a different HIV-1 genome. Certain cell-
types may be more prone to multiple infections than others. For
example, cells that live longer or tissue sites of continual feeding of
Figure 5. Summary of breakpoints in intra-tissue sequence populations. As noted along the bottom, the x-axis represents the 1200+
nucleotides incorporating the gp120 domain in HIV-1. The large transparent blue boxes represent the variable domains V1, V2, V3, V4 and V5
respectively. The variation in placement of the variable domains is due to natural genetic length variation between the patient’s data sets and to
deviation between sequencing reactions. Each plot displays the estimated location of break points found in every sequence for each patient (noted
on the upper left of the plot). A colored box indicates the estimated location of a breakpoint identified in an individual sequence using bootscanning
analysis. Each putative breakpoint is color-coded for a different tissue as shown in the figure.
doi:10.1371/journal.pone.0005065.g005
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The continuous recruitment of macrophages at infection sites and
their long lifespan makes them the perfect target for super-
infection. While the turnover of HIV-infected activated T-cells is
2–3 days, infected macrophages survive considerably longer, as
discussed above, which increases both the probability of super-
infection and the probability of recombination once super-
infection has occurred. Our finding of a large number of
recombination breakpoints distributed across the gp120 envelope
protein in abnormal tissues with high levels of replication-
competent macrophages is consistent with in vitro studies, which
showed that while a single round of viral replication in T-
lymphocytes in culture generated an average of nine recombina-
tion events, the infection of macrophages led to approximately 30
crossover events per cycle [11].
Other studies have identified macrophages as a source of the
production of recombinant viruses [11,45,46], but their role as a
major contributor to this process remains a subject of debate. The
combined results from our study demonstrate an increase in the
potential for macrophage-mediated immune evasion during HIV
disease because: 1) abnormal or damaged tissues commonly occur
during prolonged HIV disease, 2) damaged tissues recruit macro-
phages that are clearly a replication site for HIV, whereas normal
tissues do not, 3) as activated macrophages accumulate within
abnormaltissues,theymaybecomesuper-infected,thusincreasingin
the potential for the generation of recombinants, 4) any HIV-
associated disease process or HAART-associated side effect that
generates tissue damage has the potential to increase the production
of recombinants, 5) the degree of recombinants produced within an
individual may increase during HIV- or HAART-associated tissue
damage within an individual. Importantly, if macrophages are a
continued reservoir for the generation of HIV-1 intra-patient
recombinant sequences in vivo, then they are also source of continued
viral evolution and diversification over time. The current study
provides additional evidence that successful eradication of HIV-1 is
unlikely to be achieved unless new therapeutic approaches
specifically targeting tissue macrophages are developed.
Materials and Methods
Biomaterial
Frozenautopsytissuesfrompatientsandaccompanyingpathology
records were obtained from the University of California at San
Francisco AIDSand Cancer Resource(ACSR) (url: http://acsr.ucsf.
edu). The ACSR is a National Cancer Institute Funded tissue
banking program that obtains tissues from patients after appropriate
consent and the application of a de-identification procedure before
sending the tissues out to ACSR approved investigators. Clinical
histories are similarly handled ina de-identified manner.The patient
designations used throughout this study do not relate to the patients,
but were randomly generated as shorthand used by technicians who
perform the studies. The ACSR is recognized by the Office of
Biorepositories and Biospecimen Research at the National Institutes
of Health as being HIPAA compliant. Additionally, all material was
obtained under approval from the UCSF committee on human
research. Although every attempt was made to utilize similar tissues
across the subjects in the study, this was often difficult. Two subjects,
patients AM and IV, who died due to AIDS-related lymphoma,
contained no amplifiable DNA within several brain tissues
examined.
Characterization of patient specimens
All frozen tissues had parallel fixed tissues available for
hematoxylin and Eosin staining as well as immunohistochemical
staining. Tissues were stained with the tissue macrophage specific
antibody, anti-CD68, with recent tissue migrant macrophage
specific antibody, anti-MAC387 and with anti-HIVp24. All
antibodies were obtained from DAKO and were used as suggested
in the accompanying product insert and as previously described
[36].
HIV PCR, cloning and sequencing
Genomic DNA was extracted from 10–30 mg of each tissue
using the QIAmp DNA Mini Kit from Qiagen according to the
manufacturer’s instructions. A 3.3 kb HIV fragment, extending
from env to the 39LTR was amplified by PCR using the primers
EnvF1 (AAC ATG TGG AAA AAT AAC ATG GT) and NefR1
(ACT TDA AGC ACT CAA GGC AA) under the following
conditions: an initial denaturation step of 94uC for 5 min followed
by 35 cycles of 94uC for 30 sec, 55uC for 30 sec, 68uC for 3 min
20 sec, and a final extension at 68uC for 8 min, in 50 ml volume
using 600 ng of template DNA, 10 mlo f1 0 6buffer (Invitrogen),
10 mM deoxynucleoside triphosphates (Invitrogen) 60 mM of each
primer, and 2.5 units of Invitrogen Platinum-Taq polymerase.
Products were cloned into the pCR2.1-TOPO vector according to
the manufacturer’s instructions and the resultant colonies were
screened for the proper insert using an identical PCR protocol.
Sequencing was performed on approximately 20–40 clones
derived from each tissue by ELIM Biopharmaceuticals, Hayward,
CA.
Data screening and management
Because of the large amount of sequence data produced for the
study and the risk of sequence contamination or PCR over-
representation at the many levels of experimentation, a compu-
tational pipeline for screening the entire data base of sequences
was developed. The algorithm involved a feedback method from
the examination of 3.3 kb alignments and phylogenetic analysis.
The method progressed with an initial set of approximately 20
sequences from a single tissue. Any 3.3 kb sequences with 100%
identity were removed from the sample set in order to avoid over-
representation of a single variant by the polymerase chain
reaction. Sequences that contained unusual base substitution rates
or large amounts of ambiguous sites were also discarded. Next, in
order to identify potential inter-tissue contamination, a maximum-
likelihood phylogenetic tree was generated from different tissues
from the same patient. When sequence tissue populations were
non-compartmentalized, 15 additional HIV DNA clones were
generated for each non-compartmentalized tissue from the
original DNA sample. A second generation of independent clones
was sequenced and the distribution of sequences among the first
generation clones was compared to that of the second generation.
If the case arose where the second round varied significantly from
the first, a third set of sequences was obtained and to determine if
the results were reliable. The examination of multiple PCR
reactions for specific tissues enabled the confirmation of sequence
integrity in the database. Screening for inter-patient contamina-
tion was also accomplished using standard phylogenetic methods.
The protocol was designed to reduce the possibility that the data
set contained unreliable sequences due to over-amplification of
specific viral variants, problematic sequences due to PCR
contamination, sample mislabeling, inter-subject contamination,
intra-subject contamination or sequences that clustered with
significant variance over independent samplings in a phylogenetic
tree. An automated version of the phylogenetic clustering program
is available at www.bioinfoexperts.com/icarus. The cautious
selection of very high quality data is necessary in a study such as
this where final analysis is contingent upon sequence integrity.
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are not feasible for the development of a sequence data base of this
size.
The gp120 domain was identified and retrieved from the 3.3 kb
fragment using HIVbase software (http://www.hivbase.com) [48].
The CLUSTAL algorithm [49] was used to generate multiple
sequence alignments. For final gp120 alignments, a slightly
modified protocol developed by Lamers et al. [50] using
glycosylation motifs as anchors in the alignment process was used
to maximize positional homology in gap-rich regions [50].
Sequence data were deposited in Genbank.
Analysis for intra-tissue recombination
Several algorithms were combined to analyze data sets and
individual sequences for recombination [22]. Our first goal was to
identify putative recombinants within each tissue. Aligned
sequences were imported into Splitstree, (www.splitstree.org) [24]
and a preliminary network using the Neighbor Net algorithm [23]
was obtained. Splitstree currently contains one of the more robust
methods for determining the likelihood of recombination in a set
of aligned sequences [24], called a PHI-test. A PHI score with a p-
value,0.05 shows with significance that recombination occurs in
the data set. When a set of sequences produced a complex
network, along with a p-value less than 0.05, putative recombi-
nants were identified by filtering them from the data set and
recalculating the PHI-test to check whether the removal of such
sequences significantly increased the p-value. The removal of all
recombinants from the data set eventually increased the PHI-test
p-value to a level of no significance. Once the p-value for the Phi-
test was .0.05, each sequence that was removed was reinserted
individually into the Neighbor Net to make sure that it
significantly impacted the results of the PHI-test.
The program RDP was also used to identify the number of
recombinants in each tissue using the same sequence alignments as
in the previous analysis [51]. All recombinants identified for each
subject were combined and are shown in Table 8. Default settings
in the program were used for the analysis.
To identify individual putative breakpoints in each recombinant
sequence we used a sliding-window, bootscanning approach,
which computes a bootstrapped maximum-likelihood phylogenetic
tree for overlapping segments of the alignment (in our case, each
20 nucleotides) [52]. As each segment is calculated, the percent
bootstrap value with its closest relative sequence remains high until
a breakpoint is found in the compared data set. The putative
breakpoints appear in the plot as a switch in a high bootscan value
from one sequence to another related sequence. The intersection
of the bootscan plots estimates the location of the breakpoint.
Simplot software (ver3.5.1)[34] was used for the bootscanning
analysis (Figure 1). Simplot bootscans for all recombinants are
available as supplemental material. Putative breakpoints for all
recombinants were mapped as in Figure 5. These breakpoints
were not always precise; in-depth analysis showed that boot-
scanning could sometimes map breakpoints into regions,10 nt
long, whereas other times the putative breakpoint could have
occurred anywhere in a region over 200 nucleotides in length.
Statistical analysis
We used a Chi-squared test for categorical data to test whether
viral recombination across patients tended to occur with a
significantly greater frequency in normal or abnormal tissues (test
1), and whether the frequency of recombinant sequences was
significantly higher in tissues with abnormal histopathology than in
normal tissues (test 2). The Chi-squared test was performed in
SigmaStat 3.0 with and without the Yate’s Correction Factor.
Supporting Information
Supporting Materials S1
Found at: doi:10.1371/journal.pone.0005065.s001 (0.03 MB
DOC)
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